Advanced HCP CE Activity: Evolutions Through The Drug Distribution System: From Manufacturer To Patient

Add to Calendar Advanced HCP CE Activity: Evolutions Through The Drug Distribution System: From Manufacturer To Patient 1/24/2019 1:15:00 PM 1/24/2019 4:30:00 PM America/New_York For More Details: https://rutgers.cloud-cme.com/course/courseoverview?EID=279 Description: Program will review areas including gross-to-net bubble, rising drug spending in the specialty market, clinical pathways, FDAMA 114, 340B Reform, and the Right to Try Act. Presenters will provide information on new legislation which paves the path through healthcare. It will additionally address incorporating stakeholders with potentially conflicting objectives. Bristol Myers Squibb, 3401 Princeton Pike false MM/DD/YYYY


Date & Location
Thursday, January 24, 2019, 1:15 PM - 4:30 PM, Bristol Myers Squibb, 3401 Princeton Pike

Overview

Program will review areas including gross-to-net bubble, rising drug spending in the specialty market, clinical pathways, FDAMA 114, 340B Reform, and the Right to Try Act. Presenters will provide information on new legislation which paves the path through healthcare. It will additionally address incorporating stakeholders with potentially conflicting objectives.




Target Audience
Specialties - Family Medicine, General Nursing, General Pharmacy

Objectives

Overall Program Objectives:

- Discern between different ways that each entity within the drug distribution system influence the Gross-to-Net bubble.

-Assess the specialty drug market, key trends, and its implications on increasing specialty drug spending.

-Critically analyze clinical pathways and their impact on both patient care and the pharmaceutical industry.

-Review the changes that have shaped industry’s current payer communication approach and application of HCEI in promotion.

-Recognize how changes to the 340B drug discount program impact the overall drug distribution system.

-Define and recognize the historical and current federal legislations in regulating access to investigational drugs through the recently approved Right To Try Act.


  1. Understand the definition of the Gross-to-Net bubble of pharmaceuticals in the US healthcare marketplace.
  2. Identify key contributing factors to the cause of and upward trend in the Gross-to-Net bubble.
  3. Predict how current and future evolutions in the marketplace could either increase or decrease the size of the Gross-to-Net bubble.
  4. Define specialty drugs and provide an overview of the specialty market.
  5. Highlight key trends in the specialty market
  6. Provide insights on the drivers of specialty market trends.
  7. Discuss opportunities for decreased drug spend in the specialty market.
  8. Define Clinical Pathways describe an example of a clinical pathway, and identify resources for the development of for clinical pathways and analyze technology that exists to create and enforce clinical pathways.
  9. List benefits and drawbacks associated with clinical pathways.
  10. Review the history of the regulatory landscape and relevant regulations.
  11. Definition and applicability of Health Care Economic Information (HCEI).
  12. Current practice and potential challenges in communicating HCEI with payers /Discuss how the communication of HCEI may look like in the future.
  13. Define the purpose and history of the 340B drug discount program and explain how 340B drug discounts are calculated and applied.
  14. Identify covered entities under the 340B drug discount program.
  15. Assess the challenges and controversies surrounding 340B and discuss the impact of efforts to reform the 340B drug discount program.
  16. Review historical legislations of the FDA in regulating access to investigational drugs.
  17. Evaluate advantages and disadvantages of the current process of expanded access.
  18. Interpret the recently approved federal Right To Try Act.
  19. Assess the differences in which Right To Try Act diverges from the existing FDA expanded access process.
  20. Recognize key areas where healthcare professionals play a role as a result of the new legislative changes.

Registration

Before you register, please be aware that you will be required to bring your personal smartphone, tablet or laptop in order to take the mandatory pre-test and post-test for your CE Program, as well as the Evaluation.  The pre-test and post-test will only be available during the length of the CE Program.  The Evaluation portion will be available for two weeks after the CE Program ends.

If you do not take the pre-test and post-test during the CE Program, you WILL NOT receive credit.  The Evaluation MUST be completed within the two-week period of you WILL NOT receive credit.


Accreditation and Credit Designation

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians:  Rutgers Biomedical and health sciences designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists:  This knowledge-based activity qualifies for 2.00 contact hours of continuing pharmacy education credit.  Pharmacists should claim only those contact hours actually spent participating in the activity.

Nurses:  This activity is awarded 2.00 contact hours.  Nurses should only claim those contact hours actually spent participating in the activity.


Credits
AMA PRA Category 1 Credits™ (2.00 hours), ACPE Credits (2.00 hours), ANCC Contact Hours (2.00 hours)